Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Docetaxel-induced subungual hemorrhage

O Vanhooteghem1, J André, A Vindevoghel

  • 1Department of Dermatology and Venereology, Saínte Elisabeth Hospital, Namur, Belgium.

Dermatology (Basel, Switzerland)
|January 1, 1997
PubMed
Summary

Docetaxel, a taxoid chemotherapy, may cause subungual hemorrhages. Patients undergoing treatment for breast, ovarian, or lung cancer should be informed about this potential drug reaction.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decentralized worker-centred occupational management in health care: nationwide survey and alpha testing.

Occupational medicine (Oxford, England)·2025
Same author

Microwave-assisted extraction of Ulva spp. including a stage of selective coagulation of ulvan stimulated by a bio-ionic liquid.

International journal of biological macromolecules·2022
Same author

Causes of longitudinal nail splitting: a retrospective 56-case series with clinical pathological correlation.

Journal of the European Academy of Dermatology and Venereology : JEADV·2022
Same author

Position paper on a simplified histopathological classification of basal cell carcinoma: results of the European Consensus Project.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Paediatric nail consultation in an academic centre in Belgium: a 10-year retrospective study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2019
Same author

[150 years, the age of reason].

Annales de dermatologie et de venereologie·2019

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Docetaxel (RP 56976 or Taxotere) is a taxoid chemotherapy agent.
  • It is currently in phase II trials for breast, ovarian, and lung cancers.